Sustiva (Efavirenz) - Summary

SUSTIVA SUMMARY

SUSTIVA^®
(efavirenz) capsules and tablets

SUSTIVA® (efavirenz) is a human immunodeficiency virus type 1 (HIV-1) specific, non-nucleoside, reverse transcriptase inhibitor (NNRTI).

SUSTIVA (efavirenz) in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection. This indication is based on two clinical trials of at least one year duration that demonstrated prolonged suppression of HIV RNA.

SUSTIVA NEWS HIGHLIGHTS

Media Articles Related to Sustiva (Efavirenz)

Women In India Abused By Husbands At Far Greater Risk For HIV Infection
Source: HIV / AIDS News From Medical News Today [2008.08.15]

Number of New U.S. HIV Infections Gets Revised Upward
Source: MedicineNet Human Immunodeficiency Virus (HIV, AIDS) Specialty [2008.08.04]

Herpes Suppression May Not Prevent HIV Infection
Source: MedicineNet Genital Herpes In Women Specialty [2008.06.20]

CDC Report On HIV/AIDS In U.S. Should Serve As 'Wake-Up Call' For Policymakers, Health Workers, Opinion Piece Says
Source: HIV / AIDS News From Medical News Today [2008.08.14]

Abuse By Husbands Linked To Higher HIV Rate Of Married Women In India
Source: HIV / AIDS News From Medical News Today [2008.08.14]

more>>

Published Studies Related to Sustiva (Efavirenz)

Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. [2008.04.01]

Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults. [2008.01.30]

Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. [2008.01]

Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. [2007.12.15]

Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz). [2007.11]

more>>

Clinical Trials Related to Sustiva (Efavirenz)

Modification of Doses of Efavirenz According to Its Blood Concentration in HIV Patients [Active, not recruiting]

Study of Treatment of Antiretroviral-Naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz. [Active, not recruiting]

TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz [Completed]

Tenofovir Disoproxil Fumarate (DF)/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects [Active, not recruiting]

A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects [Completed]

more>>